In the BioHarmony Drug Report Database

"Preview" Icon

Idarucizumab

Praxbind (idarucizumab) is an antibody pharmaceutical. Idarucizumab was first approved as Praxbind on 2015-10-16. It has been approved in Europe to treat hemorrhage.

 

Trade Name

 

Praxbind
 

Common Name

 

idarucizumab
 

ChEMBL ID

 

CHEMBL3544996
 

Indication

 

hemorrhage
 

Drug Class

 

Monoclonal antibodies: humanized, cardiovascular indications

Image (chem structure or protein)

Idarucizumab structure rendering